Black Rock Inc. Tcr2 Therapeutics Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.0 - $1.62 $962 - $1,558	-962 Reduced 0.12%	789,911 $1.18 Million
Q4 2022 Feb 13, 2023	SELL	$0.83 - $1.44 $194,916 - $338,168	-234,839 Reduced 22.9%	790,873 $790,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $22,286 - $44,932	-11,982 Reduced 1.15%	1,025,712 $1.85 Million
Q2 2022 Aug 12, 2022	SELL	$2.11 - $2.94 $3.15 Million - $4.4 Million	-1,495,222 Reduced 59.03%	1,037,694 $3.01 Million
Q1 2022 May 12, 2022	BUY	$2.4 - $4.71 $314,810 - $617,815	131,171 Added 5.46%	2,532,916 $6.99 Million
Q4 2021 Feb 10, 2022	SELL	$4.58 - $8.34 $2.58 Million - $4.69 Million	-562,900 Reduced 18.99%	2,401,745 $11.2 Million
Q3 2021 Nov 09, 2021	BUY	$8.44 - $18.35 $232,327 - $505,120	27,527 Added 0.94%	2,964,645 $25.2 Million
Q2 2021 Aug 11, 2021	BUY	$16.41 - $24.71 $48.2 Million - $72.6 Million	2,937,118 New	2,937,118 $48.2 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.